

THE IMPACT OF ALPHA-1-ANTITRIPSIN DEFICIENCY AND PI*Z ALLELE IN LIVER FIBROSIS

José Berkeley Cotter

UEG Week Copenhagen 2023

Poster

Hepatobiliary

October 15, 2023

A prospective study of 98 patients found that alpha-1-antitripsin deficiency is associated with higher liver stiffness and transaminase levels, with diabetes, metabolic syndrome, and alcohol consumption significantly increasing fibrosis risk in Pi*Z carriers.

KEY POINTS

- Patients with alpha-1-antitripsin deficiency (n=69) had significantly higher liver stiffness (median 5.0 vs 3.8 kPa, $p<0.001$) and higher AST, ALT, ALP, and GGT levels compared to controls without liver disease (n=29), though values remained within normal ranges and without significant fibrosis in both groups.
- In patients with at least one Pi*Z allele, diabetes mellitus was associated with 8 times higher likelihood of significant liver fibrosis (LSM ≥ 7.1 kPa, $p=0.035$).
- Patients with Pi*Z mutation who had both metabolic syndrome and alcohol consumption above 25 grams daily showed significantly higher NFS and FIB-4 index values and were 6.55 times more likely to have intermediate to high risk of advanced fibrosis ($p=0.008$).
- Alpha-1-antitripsin values at diagnosis showed negative weak correlations with NFS ($s=-0.327$, $p=0.007$) and FIB-4 index ($s=-0.309$, $p=0.011$), with AAT ≥ 77 mg/dL predicting exclusion of advanced fibrosis (sensitivity 0.944, specificity 0.646).

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/933acf4e-743c-11ee-9e63-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.